Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2024-04-01 Sale | 2024-04-03 4:01 pm | GYRE THERAPEUTICS INC. | GYRE | USMAN NASSIM Director | 20,000 | $16.15 | $323,000 | 303,928 (Indirect Direct) | View |
2024-03-15 Sale | 2024-03-19 4:47 pm | GYRE THERAPEUTICS INC. | GYRE | USMAN NASSIM Director | 20,000 | $17.26 | $345,200 | 323,928 (Indirect Direct) | View |
2022-08-09 Purchase | 2022-08-10 5:19 pm | CATALYST BIOSCIENCES INC. | CBIO | USMAN NASSIM President & CEO | 3,250 | $0.47 | $1,528 | 34,165 (Indirect Direct) | View |
2022-08-09 Purchase | 2022-08-10 5:19 pm | CATALYST BIOSCIENCES INC. | CBIO | Miller Seline E. SVP Finance; Interim CFO & PAO | 3,250 | $0.47 | $1,528 | 6,500 (Direct) | View |
2022-08-09 Purchase | 2022-08-10 5:17 pm | CATALYST BIOSCIENCES INC. | CBIO | Blouse Grant E. Chief Scientific Officer | 3,250 | $0.47 | $1,528 | 9,417 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-04-01 Exercise | 2024-04-03 4:01 pm | N/A N/A | GYRE THERAPEUTICS INC. | GYRE | USMAN NASSIM Director | 20,000 | $6.93 | 303,928 (Direct) | View |
2024-04-01 Exercise | 2024-04-03 4:01 pm | N/A 2033-10-31 | GYRE THERAPEUTICS INC. | GYRE | USMAN NASSIM Director | 20,000 | $0 | 303,928 (Direct) | View |
2024-03-20 Option Award | 2024-03-21 8:31 pm | N/A 2034-03-20 | GYRE THERAPEUTICS INC. | GYRE | Nussbaum Rodney L Director | 1,866 | $0 | 1,866 (Direct) | View |
2024-03-15 Exercise | 2024-03-19 4:47 pm | N/A N/A | GYRE THERAPEUTICS INC. | GYRE | USMAN NASSIM Director | 20,000 | $6.93 | 323,928 (Direct) | View |
2024-03-15 Exercise | 2024-03-19 4:47 pm | N/A 2033-10-31 | GYRE THERAPEUTICS INC. | GYRE | USMAN NASSIM Director | 20,000 | $0 | 323,928 (Direct) | View |
2023-10-30 Other | 2023-11-22 7:55 pm | N/A N/A | GYRE THERAPEUTICS INC. | GYRE | Luo Ying Director | 2,840,376 | $0 | 11,294,404 (Indirect) | View |
2023-11-20 Option Award | 2023-11-22 7:55 pm | N/A 2030-10-31 | GYRE THERAPEUTICS INC. | GYRE | Luo Ying Director | 5,613,652 | $0 | 11,294,404 (Direct) | View |
2023-11-20 Option Award | 2023-11-22 7:49 pm | N/A 2030-10-31 | GYRE THERAPEUTICS INC. | GYRE | Ye Weiguo Chief Operating Officer | 1,665,115 | $0 | 1,665,115 (Direct) | View |
2023-11-20 Option Award | 2023-11-22 7:40 pm | N/A 2030-10-31 | GYRE THERAPEUTICS INC. | GYRE | Ma Songjiang President | 4,510,047 | $0 | 4,510,047 (Direct) | View |
2023-11-20 Option Award | 2023-11-22 7:34 pm | N/A 2030-10-31 | GYRE THERAPEUTICS INC. | GYRE | Chen Ruoyu Chief Financial Officer | 578,540 | $0 | 578,540 (Direct) | View |
2023-10-30 Other | 2023-11-22 7:27 pm | N/A N/A | GYRE THERAPEUTICS INC. | GYRE | GNI Group Ltd. GNI USA Inc. 10% Owner | 63,588,119 | $0 | 127,594,006 (Indirect) | View |
2023-11-20 Option Award | 2023-11-22 7:20 pm | N/A 2030-10-31 | GYRE THERAPEUTICS INC. | GYRE | Wu Charles C Chief Executive Officer | 170,417 | $0 | 170,417 (Direct) | View |
Ownership(A) | 2023-11-22 7:06 pm | N/A N/A | GYRE THERAPEUTICS INC. | GYRE | Ma Songjiang President | 0 | $0 | 2,942,467 (Indirect) | View |
2023-10-31 Option Award | 2023-11-01 06:15 am | N/A 2033-10-31 | GYRE THERAPEUTICS INC. | GYRE | Luo Ying Director | 1,866 | $0 | 1,866 (Direct) | View |
2023-10-31 Option Award | 2023-11-01 06:15 am | N/A 2033-10-31 | GYRE THERAPEUTICS INC. | GYRE | Eastling Thomas Wilson Director | 316,518 | $0 | 316,518 (Direct) | View |
2023-10-31 Option Award | 2023-11-01 06:15 am | N/A 2033-10-31 | GYRE THERAPEUTICS INC. | GYRE | Parry Renate Director | 1,866 | $0 | 1,866 (Direct) | View |
2023-10-31 Option Award | 2023-11-01 06:15 am | N/A 2033-10-31 | GYRE THERAPEUTICS INC. | GYRE | Chen Ruoyu Interim CFO | 34,380 | $0 | 34,380 (Direct) | View |
2023-10-31 Option Award | 2023-11-01 06:15 am | N/A 2033-10-31 | GYRE THERAPEUTICS INC. | GYRE | USMAN NASSIM Director | 343,518 | $0 | 343,518 (Direct) | View |
2023-10-31 Option Award | 2023-11-01 06:15 am | N/A 2033-10-31 | GYRE THERAPEUTICS INC. | GYRE | Ying Han Director | 1,866 | $0 | 1,866 (Direct) | View |
2023-10-31 Option Award | 2023-11-01 06:15 am | N/A 2033-10-31 | GYRE THERAPEUTICS INC. | GYRE | Carmichael Gordon Director | 1,866 | $0 | 1,866 (Direct) | View |
Ownership | 2023-10-27 8:01 pm | N/A N/A | CATALYST BIOSCIENCES INC. | CBIO | GNI Group Ltd. GNI USA Inc. 10% Owner | 0 | $0 | 129,666,521 (Indirect) | View |
2023-10-27 Other | 2023-10-27 7:56 pm | N/A N/A | CATALYST BIOSCIENCES INC. | CBIO | GNI Hong Kong Ltd 10% Owner | 5,381,881 | $0 | 5,371,304 (Direct) | View |
2023-08-31 Disposition | 2023-09-01 4:07 pm | N/A N/A | CATALYST BIOSCIENCES INC. | CBIO | Miller Seline E. SVP Finance; Interim CFO & PAO | 7 | $0 | 0 (Direct) | View |
2023-08-31 Disposition | 2023-09-01 4:07 pm | N/A N/A | CATALYST BIOSCIENCES INC. | CBIO | USMAN NASSIM President & CEO | 34 | $0 | 0 (Direct) | View |
2023-08-31 Disposition | 2023-09-01 4:07 pm | N/A N/A | CATALYST BIOSCIENCES INC. | CBIO | Hunt Andrea Director | 28 | $0 | 0 (Direct) | View |
2023-08-31 Disposition | 2023-09-01 4:07 pm | N/A N/A | CATALYST BIOSCIENCES INC. | CBIO | GNI Group Ltd. GNI Hong Kong Ltd 10% Owner | 6,267 | $0 | 0 (Direct) | View |
2023-08-31 Disposition | 2023-09-01 4:07 pm | N/A N/A | CATALYST BIOSCIENCES INC. | CBIO | LAWLOR AUGUSTINE Director | 49 | $0 | 0 (Direct) | View |
Ownership | 2023-01-05 4:06 pm | N/A N/A | CATALYST BIOSCIENCES INC. | CBIO | GNI Group Ltd. GNI Hong Kong Ltd 10% Owner | 0 | $0 | 129,666,521 (Direct) | View |
2022-02-11 Option Award | 2022-02-23 4:08 pm | N/A 2032-02-11 | CATALYST BIOSCIENCES INC. | CBIO | Miller Seline E. SVP Finance; Interim CFO & PAO | 107,500 | $0 | 107,500 (Direct) | View |